Satheesh Chiradoni Thungappa

2.1k total citations · 1 hit paper
13 papers, 305 citations indexed

About

Satheesh Chiradoni Thungappa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Satheesh Chiradoni Thungappa has authored 13 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Satheesh Chiradoni Thungappa's work include Lung Cancer Treatments and Mutations (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer Mechanisms and Therapy (2 papers). Satheesh Chiradoni Thungappa is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer Mechanisms and Therapy (2 papers). Satheesh Chiradoni Thungappa collaborates with scholars based in India, Italy and Spain. Satheesh Chiradoni Thungappa's co-authors include Alexandra Heurgué, Alexander Vasilyev, George Lau, Stephen L. Chan, Bruno Sangro, Kabir Mody, Ghassan K. Abou‐Alfa, Robin Kate Kelley, Philip He and Masatoshi Kudo and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Satheesh Chiradoni Thungappa

9 papers receiving 302 citations

Hit Papers

Phase 3 randomized, open-label, multicenter study of trem... 2022 2026 2023 2024 2022 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
    2022 259 citations Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satheesh Chiradoni Thungappa India 4 201 174 71 67 65 13 305
Alexander Vasilyev Russia 2 196 1.0× 158 0.9× 74 1.0× 66 1.0× 61 0.9× 3 284
Philip He United States 7 270 1.3× 279 1.6× 106 1.5× 82 1.2× 92 1.4× 22 459
Xuqi Sun China 8 192 1.0× 115 0.7× 72 1.0× 76 1.1× 47 0.7× 27 282
Oxana Crysler United States 7 214 1.1× 270 1.6× 62 0.9× 96 1.4× 121 1.9× 25 432
Ziyu Xun China 11 112 0.6× 175 1.0× 94 1.3× 57 0.9× 67 1.0× 35 340
Daniel Almquist United States 8 102 0.5× 169 1.0× 85 1.2× 103 1.5× 48 0.7× 18 303
Songqiang Zhou China 9 178 0.9× 107 0.6× 82 1.2× 69 1.0× 56 0.9× 15 294
Maria Aurelia Barbera Italy 9 104 0.5× 134 0.8× 70 1.0× 60 0.9× 50 0.8× 19 284
Quanren Wang China 1 131 0.7× 245 1.4× 148 2.1× 29 0.4× 82 1.3× 2 368
Derek-Zhen Xu China 5 124 0.6× 91 0.5× 28 0.4× 31 0.5× 47 0.7× 6 171

Countries citing papers authored by Satheesh Chiradoni Thungappa

Since Specialization
Citations

This map shows the geographic impact of Satheesh Chiradoni Thungappa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satheesh Chiradoni Thungappa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satheesh Chiradoni Thungappa more than expected).

Fields of papers citing papers by Satheesh Chiradoni Thungappa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satheesh Chiradoni Thungappa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satheesh Chiradoni Thungappa. The network helps show where Satheesh Chiradoni Thungappa may publish in the future.

Co-authorship network of co-authors of Satheesh Chiradoni Thungappa

This figure shows the co-authorship network connecting the top 25 collaborators of Satheesh Chiradoni Thungappa. A scholar is included among the top collaborators of Satheesh Chiradoni Thungappa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satheesh Chiradoni Thungappa. Satheesh Chiradoni Thungappa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Thomas, R. Brent, et al.. (2022). Kirsten Rat Sarcoma Mutation in South Indians with Non-Small Lung Cancer. 2(1). 3–8.
4.
Abou‐Alfa, Ghassan K., Stephen L. Chan, Masatoshi Kudo, et al.. (2022). Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. Journal of Clinical Oncology. 40(4_suppl). 379–379. 259 indexed citations breakdown →
5.
6.
Hazarika, Diganta, et al.. (2020). Translational relevance of androgen receptor immunohistochemistry scoring systems for data harmonization in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 38(15_suppl). 1078–1078. 1 indexed citations
7.
Thungappa, Satheesh Chiradoni, et al.. (2020). Survival outcomes of metaplastic breast carcinoma: An Indian tertiary care center data.. Journal of Clinical Oncology. 38(15_suppl). e12579–e12579. 1 indexed citations
8.
Thungappa, Satheesh Chiradoni, et al.. (2018). Indian experience of lenvatinib in radio-iodine refractory differentiated thyroid cancer.. Journal of Clinical Oncology. 36(15_suppl). e18107–e18107.
9.
Somashekhar, S. P., Amit Rauthan, Amit Agarwal, et al.. (2018). A prospective observational multicentric pan India study of lenvatinib in radio-iodine refractory advanced differentiated thyroid cancer.. Journal of Clinical Oncology. 36(15_suppl). e18106–e18106.
10.
Thungappa, Satheesh Chiradoni, et al.. (2017). Modified DOF regimen in advanced stomach cancer – A single centre experience from Bangalore.. Annals of Oncology. 28. iii44–iii44.
11.
Patil, Shekhar, et al.. (2017). Retrospective multicentric analysis of Indian patients with metastatic renal cell carcinoma on first-line sunitinib 2/1 schedule. Annals of Oncology. 28. x84–x84. 1 indexed citations
12.
Thungappa, Satheesh Chiradoni, et al.. (2017). P2.03b-064 Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine. Journal of Thoracic Oncology. 12(1). S974–S975. 3 indexed citations
13.
Thungappa, Satheesh Chiradoni, et al.. (2017). Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…. ESMO Open. 2(1). e000162–e000162. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Vasilyev Breakdown of academic impact, for papers by Philip He Breakdown of academic impact, for papers by Xuqi Sun Breakdown of academic impact, for papers by Oxana Crysler Breakdown of academic impact, for papers by Ziyu Xun Breakdown of academic impact, for papers by Daniel Almquist Breakdown of academic impact, for papers by Songqiang Zhou Breakdown of academic impact, for papers by Maria Aurelia Barbera Breakdown of academic impact, for papers by Quanren Wang Breakdown of academic impact, for papers by Derek-Zhen Xu
Rankless by CCL
2026